{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T02:02:40Z","timestamp":1784599360682,"version":"3.55.0"},"reference-count":25,"publisher":"ARAN Ediciones","issue":"2","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hipertensi\u00f3n y Riesgo Vascular"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.hipert.2020.02.002","type":"journal-article","created":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T19:20:02Z","timestamp":1584127202000},"page":"64-71","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Coraz\u00f3n y ri\u00f1\u00f3n en la diabetes: efectos de los glucos\u00faricos"],"prefix":"10.20960","volume":"37","author":[{"given":"A.","family":"Tejedor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"8588","reference":[{"key":"10.1016\/j.hipert.2020.02.002_bib0130","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s13105-012-0153-3","article-title":"Autocrine modulation of glucose transporter SGLT2 by IL-6 and TNF-\u03b1 in LLC-PK(1) cells","volume":"68","author":"Maldonado-Cervantes","year":"2012","journal-title":"J Physiol Biochem."},{"key":"10.1016\/j.hipert.2020.02.002_bib0135","doi-asserted-by":"crossref","first-page":"e54442","DOI":"10.1371\/journal.pone.0054442","article-title":"Effects of SGLT2 inhibition in human kidney proximal tubular cells\u2014renoprotection in diabetic nephropathy?","volume":"8","author":"Panchapakesan","year":"2013","journal-title":"PLoS One."},{"key":"10.1016\/j.hipert.2020.02.002_bib0140","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.2337\/diabetes.54.12.3427","article-title":"Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes","volume":"54","author":"Rahmoune","year":"2005","journal-title":"Diabetes."},{"key":"10.1016\/j.hipert.2020.02.002_bib0145","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/dmrr.2407","article-title":"Sodium-glucose cotransporter 2-mediated oxidative stress augments advanced glycation end products-induced tubular cell apoptosis","volume":"29","author":"Maeda","year":"2013","journal-title":"Diabetes Metab Res Rev."},{"key":"10.1016\/j.hipert.2020.02.002_bib0150","doi-asserted-by":"crossref","first-page":"e100777","DOI":"10.1371\/journal.pone.0100777","article-title":"Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin ameliorates glucose homeostasis and diabetic nephropathy in db\/db mice","volume":"9","author":"Terami","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.hipert.2020.02.002_bib0155","first-page":"2526","article-title":"Succinate receptor GPR91 provides a direct link between high glucose levels and renin release in murine and rabbit kidney","volume":"118","author":"Toma","year":"2008","journal-title":"J Clin Invest."},{"key":"10.1016\/j.hipert.2020.02.002_bib0160","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1681\/ASN.V4140","article-title":"Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes","volume":"4","author":"Remuzzi","year":"1993","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.hipert.2020.02.002_bib0165","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1681\/ASN.V113477","article-title":"Effect of angiotensin-converting enzyme inhibition on glomerular basement membrane permeability and distribution of zonula occludens-1 in MWF rats","volume":"11","author":"Macconi","year":"2000","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.hipert.2020.02.002_bib0170","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.2337\/dc11-0235","article-title":"Impaired fasting glucose is associated with renal hyperfiltration in the general population","volume":"34","author":"Melsom","year":"2011","journal-title":"Diabetes Care."},{"key":"10.1016\/j.hipert.2020.02.002_bib0175","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation."},{"key":"10.1016\/j.hipert.2020.02.002_bib0180","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/ki.1992.126","article-title":"Increased glomerular filtration rate as a predictor of diabetic nephropathy\u2014an 8-year prospective study","volume":"41","author":"Rudberg","year":"1992","journal-title":"Kidney Int."},{"key":"10.1016\/j.hipert.2020.02.002_bib0185","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ejphar.2013.05.014","article-title":"Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice","volume":"715","author":"Tahara","year":"2013","journal-title":"Eur J Pharmacol."},{"key":"10.1016\/j.hipert.2020.02.002_bib0190","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/j.jacc.2009.12.045","article-title":"Inflammatory markers and incident heart failure risk in older adults: The Health ABC (Health Aging, and Body Composition) study","volume":"55","author":"Kalogeropoulos","year":"2010","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.hipert.2020.02.002_bib0195","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3389\/fphys.2018.00114","article-title":"Oxidative stress and NLRP3-inflammasome activity as significant drivers of diabetic cardiovascular complications: Therapeutic implications","volume":"9","author":"Sharma","year":"2018","journal-title":"Front. Physiol."},{"key":"10.1016\/j.hipert.2020.02.002_bib0200","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1124\/jpet.116.235069","article-title":"Empagliflozin protects against diet-induced NLRP-3 inflammasome activation and lipid accumulation","volume":"359","author":"Benetti","year":"2016","journal-title":"J Pharmacol Exp Ther."},{"key":"10.1016\/j.hipert.2020.02.002_bib0205","doi-asserted-by":"crossref","first-page":"e0143396","DOI":"10.1371\/journal.pone.0143396","article-title":"Amelioration of hyperglycemia with a sodium-glucose cotransporter 2 inhibitor prevents macrophage-driven atherosclerosis through macrophage foam cell formation suppression in type 1 and type 2 diabetic mice","volume":"10","author":"Terasaki","year":"2015","journal-title":"PLoS ONE."},{"key":"10.1016\/j.hipert.2020.02.002_bib0210","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10557-017-6725-2","article-title":"SGLT-2 inhibition with dapagliflozin reduces the activation of the Nlrp3\/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. Further augmentation of the effects with saxagliptin, a DPP4 inhibitor","volume":"31","author":"Ye","year":"2017","journal-title":"Cardiovasc Drugs Ther."},{"issue":"3 Suppl","key":"10.1016\/j.hipert.2020.02.002_bib0215","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjmed.2009.12.004","article-title":"Glycemic control and complications in type 2 diabetes mellitus","volume":"123","author":"Stolar","year":"2010","journal-title":"Am J Med."},{"key":"10.1016\/j.hipert.2020.02.002_bib0220","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hipert.2020.02.002_bib0225","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.hipert.2020.02.002_bib0230","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S2213-8587(19)30180-9","article-title":"Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: An analysis from the DECLARE-TIMI 58 randomised trial","volume":"7","author":"Mosenzon","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.hipert.2020.02.002_bib0235","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1007\/s00125-016-4008-2","article-title":"The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes","volume":"59","author":"Cherney","year":"2016","journal-title":"Diabetologia."},{"key":"10.1016\/j.hipert.2020.02.002_bib0240","doi-asserted-by":"crossref","first-page":"405","DOI":"10.7326\/0003-4819-156-6-201203200-00003","article-title":"Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: A randomized trial","volume":"156","author":"Wilding","year":"2012","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.hipert.2020.02.002_bib0245","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S2213-8587(18)30051-2","article-title":"Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables","volume":"6","author":"Ahlqvist","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.hipert.2020.02.002_bib0250","unstructured":"Recomendaciones en el tratamiento farmacol\u00f3gico de la DM2 del Grupo de Diabetes, Obesidad y Nutrici\u00f3n de la SEMI. Disponible en: https:\/\/www.fesemi.org\/sites\/default\/files\/documentos\/publicaciones\/recomendaciones_dm2_semi_2020_v3.2.1.pdf"}],"container-title":["Hipertensi\u00f3n y Riesgo Vascular"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1889183720300052?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1889183720300052?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T01:15:18Z","timestamp":1784596518000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1889183720300052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S1889183720300052"],"URL":"https:\/\/doi.org\/10.1016\/j.hipert.2020.02.002","relation":{},"ISSN":["1889-1837"],"issn-type":[{"value":"1889-1837","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Coraz\u00f3n y ri\u00f1\u00f3n en la diabetes: efectos de los glucos\u00faricos","name":"articletitle","label":"Article Title"},{"value":"Hipertensi\u00f3n y Riesgo Vascular","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hipert.2020.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Espa\u00f1a, S.L.U. on behalf of SEH-LELHA.","name":"copyright","label":"Copyright"}]}}